ADNI-PET data is available on ADNI website (<http://adni.loni.usc.edu/>). There are ethical restrictions on sharing patients\'s dataset because it contains potentially identifying or sensitive patient information. The authors had no special access privileges to the data others would not have. It means that any interested researchers can replicate the current study findings in their entirety by directly obtaining the data from ADNI\'s website and combining their own error map dataset.

Background {#sec005}
==========

Integrated positron emission tomography (PET) / magnetic resonance (MR) systems have been currently widely distributed (over 100 institutions in the world). Previous studies have revealed that 2-deoxy-2-\[18F\]fluoro-D-glucose (FDG)-PET/MR is useful in the evaluation of neurodegenerative diseases \[[@pone.0233886.ref001]--[@pone.0233886.ref006]\]. Additionally, combined PET/MR not only provides detailed brain anatomy, but the immediate availability of coregistered anatomy might even improve PET image quality by facilitating the correction of partial volume effects and/or motion artifacts \[[@pone.0233886.ref007], [@pone.0233886.ref008]\]. However, several technical challenges should be solved to exploit the full performance of PET/MR. One of the limitations in need of improvement is that of attenuation correction (AC) using MR imaging data (MRAC) \[[@pone.0233886.ref009]\]. On PET/MR system, it is difficult to derive AC-maps from conventional MR-data due to the lack of a relationship between photon attenuation and MR signal intensity. To solve this problem, several AC-methods (i.e. Dixon-based AC, Atlas-based AC, Model-based AC, zero echo time MRI based AC and ultrashort echo time MRI based AC) have been proposed from vendors and researchers \[[@pone.0233886.ref009], [@pone.0233886.ref010]\]. For clinical use, Dixon-based four-class segmentation approaches (i.e. air, lung, fat and soft tissue) was implemented into both the Biograph mMR (Siemens Healthcare, Erlangen, Germany) and SIGNA PET/MR (GE Healthcare, Waukesha, WI, USA). However, these methods are not recommended for brain studies, because neglecting bone introduces a significant bias in cortical areas \[[@pone.0233886.ref011]\]. One of the alternative methods currently implemented on clinical PET/MR scanners is the atlas-based method \[[@pone.0233886.ref012], [@pone.0233886.ref013]\]. This method is comparably accurate in supratentorial regions, but not accurate enough in the temporal lobe and in the infratentorial region, where FDG uptake is underestimated. This variability of error distribution may impact the diagnostic accuracy of FDG PET in several diseases, including Alzheimer's disease (AD). Quantitative evaluation of FDG-PET typically relies on a normalization of local FDG uptake to that in dedicated anatomical regions (e.g. cerebellum and thalamus) or to the whole brain average. If the regions with overestimated FDG accumulation are normalized to an underestimated region, or vice versa, the result could be under- or over-diagnosis of AD. However, the impact of the vendor-provided MRAC on the accuracy of diagnosis of AD has not been reported in the literature.

The aim of this paper was to clarify the clinical utility of FDG-PET from PET/MR, with vendor-provided atlas-based MRAC, for the diagnosis of AD. The analysis was performed on simulated data that combined real patient data from two institutions (Institution A (InA) and B (InB)) and Alzheimer Disease Neuroimaging Initiative (ADNI) data, well-established large cohort data. The probability of AD was calculated using fully automated procedures in commercially available software.

Materials and methods {#sec006}
=====================

This study was approved by each local institutional review board, cantonal ethics committee Zurich and Institutional Review Board of Mayo Clinic. All subjects provided signed informed consent prior to the examinations. All experiments were performed in accordance with relevant guidelines and regulations. We recruited 47 patients, from two institutions, who underwent both PET/CT and PET/MR (GE SIGNA) examination. In addition, we extracted 203 subjects from the ADNI dataset. From the PET raw data acquired on PET/MR, two FDG-PET series were generated, using either the vendor-provided atlas-based MRAC or CTAC. Following spatial normalization to MNI space, we calculated the error map for each patient, as PET~MRAC~/PET~CTAC~. We multiplied each of these 47 error maps with each of the 203 ADNI cases in MNI space. This resulted in 203\*47 = 9541 datasets (**[Fig 1](#pone.0233886.g001){ref-type="fig"}**). To evaluate the probability of AD in each resulting image, a cumulative t-value was calculated using a fully automated method in commercially-available software (**[S1 Fig](#pone.0233886.s001){ref-type="supplementary-material"}**). The diagnostic accuracy for the discrimination of AD and predicting progression from mild cognitive impairment (MCI) to AD were evaluated in simulated images compared with the original ADNI images (**[Fig 1](#pone.0233886.g001){ref-type="fig"}**).

![Summarized workflow used to generate the simulated PET dataset with error derived from MRAC.\
A detailed description of the procedure is provided in the materials and methods section.](pone.0233886.g001){#pone.0233886.g001}

Alzheimer Disease Neuroimaging Initiative (ADNI) data {#sec007}
-----------------------------------------------------

Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). For up-to-date information, see [www.adni-info.org](http://www.adni-info.org/). The authors had no special access privileges to the data others would not have. It means that any interested researchers can replicate the current study findings in their entirety by directly obtaining the data from ADNI\'s website and combining their own error map dataset.

From ADNI-1 data, we extracted 203 participants (76.0±6.3 years, 129 males, 48 healthy, 59 AD and 96 MCI participants). Out of 96 MCI participants, 33 progressed to AD at 24 months after imaging. The inclusion criteria were: completeness of date of birth, baseline diagnosis (healthy, MCI, or AD) and the diagnosis at 24 months after imaging. All PET images were of sufficient quality for visual scoring and for software-based analysis using PMOD's Alzheimer Discrimination tool PALZ (PMOD Technologies LLC, Zurich, Switzerland) \[[@pone.0233886.ref014], [@pone.0233886.ref015]\]. The baseline PET data was utilized. The reported FDG-PET imaging parameters were: injected dose, 185 MBq (5 mCi), dynamic 3D acquisition, six 5-min frames 30--60 min post injection.

Patients {#sec008}
--------

We recruited 47 patients who underwent both PET/CT and PET/MR for oncologic staging from two institutions (InA and InB). Twenty patients (11 males and 9 females, 61.6±12.4 years) with lymphoma, lung cancer, head and neck cancer, pancreatic cancer, pleural methotelioma, uterine carcinoma, cervical carcinoma and malignant melanoma at InA were collected by summing the cohorts recruited in previous studies \[[@pone.0233886.ref012], [@pone.0233886.ref016]\]. The other twenty-seven patients (15 males and 12 females, 60.0±13.0 years) with lymphoma, pheochromocytoma, myeloma, melanoma, Merker-cell cancer, lung cancer, pancreatic cancer, breast cancer and dementia at InB were collected from another previous study, after excluding 3 patients. Two of these three excluded patients had infarction and one had multiple brain metastases \[[@pone.0233886.ref017]\]. A neuroradiologist (T.S.) reviewed and confirmed that all included patients were free of brain abnormalities.

PET/CT and PET/MR acquisition {#sec009}
-----------------------------

The averaged injected dose of FDG was 233.2±42.1MBq (range, 179.4--325.7 MBq) at InA and 534±42 MBq \[range, 434--566 MBq\] at InB. The PET/CT acquisition followed the standard protocol for a clinical oncology study. InA used a Discovery 690 PET/CT (GE Healthcare) and InB used a Discovery RX/MI/690/710 PET/CT (GE Healthcare). A helical whole-body CT scan (120 kV, slice thickness 3.3mm, pixel dimensions 1.4×1.4 mm^2^ at InA and 120--140 kV, slice thickness 3.75--5.00 mm, pixel size 1.37×1.37 mm^2^ at InB) was acquired for AC of PET data and diagnostic purposes \[[@pone.0233886.ref018]\]. Subsequently, a whole-body PET dataset including the head was acquired. Immediately before or after the PET/CT scan, patients were transferred to the integrated PET/MR scanner (SIGNA PET/MR, GE Healthcare), and a brain PET/MR scan was performed as part of the study examination. A 2 min PET acquisition at InA and a 10 min acquisition at InB with a standard head coil (8-channnel HD Brain; GE Healthcare) was performed. The duration between tracer injection and PET acquisition was 116±31 min \[range, 48--183 min\] at InA and 112±15 min \[range, 66--138 min\] at InB.

During the PET acquisition on the PET/MR, liver acquisition with volume acceleration flex (LAVA-Flex) T1w images (axial acquisition, TR \~ 4 ms, TE 2.23 ms, flip angle 5°, slice thickness 5.2 mm with 2.6 mm overlap, 120 slices, pixel size 1.95 × 1.95 mm^2^, number of excitations (NEX) 0.9, acquisition time: 18 s) were acquired for vendor-provided atlas-based AC \[[@pone.0233886.ref013]\].

Attenuation map generation {#sec010}
--------------------------

The atlas AC map was calculated from the LAVA-Flex T1w images using the vendor-provided default processing \[[@pone.0233886.ref018]\].

For the generation of CTAC, the processing steps detailed below were performed using custom Matlab scripts and PMOD 3.8. The co-registered CTAC map was generated as follows. First, the original head CT was exported from the PET/CT scanner and converted into an AC map using a Matlab version of the same bilinear mapping implemented in the SIGNA PET/MRI. From this map, the CT table was removed manually. A threshold was set to extract the outside air component from the CTAC map. None of the images used in this study contained artifacts likely to affect air thresholding. To derive the registration parameters necessary to match CT to LAVA-Flex T1w, a normalized mutual information matching algorithm (PMOD) was used and the final matching was performed using custom Matlab routines. Finally, the CTAC map was superimposed on the atlas AC map, replacing it \[[@pone.0233886.ref013]\].

Reconstruction of PET images {#sec011}
----------------------------

Only the list-mode raw PET data from the PET/MR examination were used. PET images were reconstructed twice, using either atlas AC or silver-standard CTAC using the following parameters: InA, fully 3D ordered subset expectation maximization iterative reconstruction (OSEM), subsets 28, iterations 8, pixel size 1.17 × 1.17 mm^2^, point spread function (PSF) modeling, transaxial post-reconstruction Gaussian filter cutoff 3mm, axial filter 1:4:1, scatter, normalization, dead-time and decay corrections, TOF reconstruction; InB, fully 3D OSEM, subsets 28, iterations 3, pixel size 1.56 × 1.56 mm^2^, PSF modeling, transaxial post-reconstruction Gaussian filter cutoff 3mm, axial filter 1:4:1, scatter, normalization, dead-time and decay corrections, TOF reconstruction.

Automated software for AD probability assessment {#sec012}
------------------------------------------------

Automated AD probability assessment was performed in a commercially available tool (PMOD Alzheimer's Discrimination, PALZ). This software tool has been used in multiple large cohort studies, e.g. ADNI, NEST-DD and SEAD-Japan \[[@pone.0233886.ref015], [@pone.0233886.ref019], [@pone.0233886.ref020]\]. The software ran the following procedures, in a fully automated workflow, in accordance to the methods described by Herholz et al. \[[@pone.0233886.ref021]\]. First, spatial normalization is performed by transforming the original images to the SPM99 PET template, followed by smoothing with a Gaussian filter of 12 x 12 x 12 mm \[[@pone.0233886.ref022], [@pone.0233886.ref023]\]. In these images, voxel values are normalized by dividing each image voxel value by the mean voxel value, averaged within a mask representing voxels in which FDG uptake is typically preserved even in AD patients. The expected value in each voxel is calculated from a pre-stored, age-matched, reference PET database of healthy controls. This is achieved by combining voxel-wise regression parameters, where brain atrophy was taken into account by adjustment of the normal reference values using linear regression by age. By comparing the voxel-wise differences between expected value and the patient-specific value, a Student's t-value is calculated \[[@pone.0233886.ref024]\]. The AD t-sum is calculated by summing the t-value in predefined AD-related voxels. Finally, the PET Score was calculated as log2 (AD t-sum/11089 +1), for which the 95% prediction limit (11089) of AD t-sum was established in the NEST-DD multi-center trial \[[@pone.0233886.ref015]\]. This analysis was initially performed in all 203 ADNI-PET data (e.g. *PETScore~ADNI−j~*) before multiplication with the 47 error maps. The detailed procedure is shown in [S1 Fig](#pone.0233886.s001){ref-type="supplementary-material"}.

Creation of simulated data: ADNI-data with Atlas-AC {#sec013}
---------------------------------------------------

All simulation steps were performed in MNI space with same spatial resolution (2 mm isotropic voxels). First, we divided the locally acquired PET images based on atlas AC by those based on CTAC (47 patients) (e.g. *~Error~PET^pt−i^*). Second, the resulting images were spatially normalized to the SPM99 PET template using the transformation calculated for PET images based on CTAC to the template, then a Gaussian filter of 12 x 12 x 12 mm full-width half-maximum was applied (${}_{Error}^{Norm}PET^{pt - i}$). A brain mask was applied to avoid distortion at the edges of the measured data. These steps were designed to replicate the preprocessing steps used in the PMOD Alzheimer's Discrimination tool, as used to calculate PET score. Therefore, the resulting images were the error maps (between atlas AC and CTAC) in the same image space as the spatially normalized ADNI PET data (*^Norm^PET~ADNI−j~*). Third, we multiplied each of the 203 normalized ADNI data with each of the 47 normalized error maps, resulting in 203\*47 = 9541 normalized PET images (e.g. ${}_{Error}^{Norm}PET_{ADNI - j}^{pt - i}$). Thus, the value-error was simply imposed in a voxel-wise manner and further PET score calculation was performed without additional need for spatial deformation or filtering. Therefore, we expected any bias due to impaired spatial normalization or differences in PET acquisition protocol to be minimized. For each of these 9541 images, PALZ analysis (from the second to fifth analysis step) was performed to calculate the PET score (${PETScore}_{ADNI - j}^{pt - i}$). This workflow is summarized in **[Fig 1](#pone.0233886.g001){ref-type="fig"}**.

Evaluation of diagnostic accuracy for Alzheimer's disease {#sec014}
---------------------------------------------------------

First, to clarify the distribution of MRAC error, we calculated the averaged error in whole SPM 99 PET voxels, whole AD-related voxels and whole non-AD related voxels in each of the 47 normalized error map $\left( {{}_{Error}^{Norm}PET^{pt - i}} \right)$. Second, we calculated the difference in PET score (${PETScore}_{ADNI - j}^{pt - i}{- PETScore}_{ADNI - j}$) for all 9541 datasets. To reveal whether differing PET acquisition protocols affected the simulation results, we additionally compared PET score between InA and InB.

We evaluated the diagnostic accuracy from two points of view. First was the diagnostic accuracy of discrimination of AD from normal patients. Based on a previous study, the cut-off is PET score = 1 \[[@pone.0233886.ref015]\]. Second was the diagnostic accuracy of prediction of conversion from MCI to AD \[[@pone.0233886.ref014]\]. For the prediction from MCI to AD, the PET score cut-off is 0.79, defined using the Youden index \[[@pone.0233886.ref025]\].

We calculated sensitivity and specificity using the data for each error map multiplied by each PET image. We created Bland-Altman plots of PET scores in the best 3 and the worst 3 cases \[[@pone.0233886.ref026]\]. The confidence intervals (CI) were calculated using the original data.

Results {#sec015}
=======

In 47 normalized error map, whole voxels of SPM 99 were slightly underestimated (-1.37%±1.98%). In detail, AD-related voxels were less underestimated than non AD-related voxels (-0.86%±2.03% vs. -1.59%±1.98%). As a result, compared with the reference PET score derived from original 203 ADNI data, the PET score from 9541 simulated data was slightly underestimated (-0.068±0.046). There was no statistical difference in PET score between the patient groups from InA and InB (-0.070±0.045 vs. -0.066±0.046; p = 0.392).

Neither accuracy nor specificity for the discrimination of AD patients from normal controls were significantly impaired by MRAC, but sensitivity was slightly impaired when using 5 out of 47 error maps (original vs. error; 83.2% \[CI 75.0%-89.0%\], 83.3% \[CI 74.2%-89.8%\] and 83.1% \[CI 75.6%-88.3%\] vs. 82.7% \[range 80.4--85.0%\], 78.5% \[range 72.9--83.3%,\] and 86.1% \[range 81.4--89.8%\]) (**[Table 1](#pone.0233886.t001){ref-type="table"}** and [**Fig** 2A](#pone.0233886.g002){ref-type="fig"}).

![Accuracy, sensitivity and specificity in original ADNI data and each of the 47 datasets with simulated MRAC error.\
Discrimination of Alzheimer's disease (AD) patients from normal subjects (A) and the prediction of mild cognitive impairment (MCI) progression to AD. 95% confidence intervals are shown as Whisker plots. All 47 datasets maintain their accuracy and specificity compared with the original data, while five out of 47 error datasets slightly impaired the sensitivity for the discrimination of AD.](pone.0233886.g002){#pone.0233886.g002}

10.1371/journal.pone.0233886.t001

###### Diagnostic accuracy of original PET data and simulated MRAC PET data.

![](pone.0233886.t001){#pone.0233886.t001g}

                                                                           Original                  MRAC (47 datasets)           
  ---------------------------------------------- ------------------------- ------------------------- -------------------- ------- -------
  **Discrimination AD from normal**              Accuracy                  83.2% (CI: 75.0--89.0%)   82.7%                80.4%   85.0%
  Sensitivity                                    83.3% (CI: 74.2--89.8%)   78.5%                     72.9%                83.3%   
  Specificity                                    83.1% (CI 75.6--88.3%)    86.1%                     81.4%                89.8%   
  **Prediction of progression from MCI to AD**   Accuracy                  62.5% (CI: 53.3--69.3%)   64.8%                61.5%   66.7%
  Sensitivity                                    78.8% (CI: 65.4--88.6%)   75.7%                     66.7%                81.8%   
  Specificity                                    54.0% (CI: 47.0--69.1%)   59.0%                     50.8%                63.5%   

AD, Alzheimer's disease; MCI, mild cognitive impairment; MRAC, MR-based attenuation correction.

The accuracy, sensitivity, or specificity for predicting progression from MCI to AD during 2-year follow-up were maintained by MRAC (62.5% \[CI 53.3%-69.3%\], 78.8% \[CI 65.4%-88.6%\] and 54.0% \[CI 47.0%-69.1%\] vs. 64.8% \[range 61.5--66.7%\], 75.7% \[range 66.7--81.8%,\] and 59.0% \[range 50.8--63.5%\]) (**[Table 1](#pone.0233886.t001){ref-type="table"}** and **[Fig 2B](#pone.0233886.g002){ref-type="fig"}**). The worst 3 error maps showed a tendency towards underestimation of PET scores (**[Fig 3](#pone.0233886.g003){ref-type="fig"}**). A representative case is shown in **[Fig 4](#pone.0233886.g004){ref-type="fig"}**.

![Bland-Altman plots of best three cases (A) and worst three cases (B) for 203 simulated PET data with MRAC error. The PET score tends to be underestimated, especially in the worst cases.](pone.0233886.g003){#pone.0233886.g003}

![Representative case.\
The original PET images extracted from ADNI-cohort (A). After spatial and value normalization, the normalized images were acquired (B). The voxel-wise differences between the expected and patient-specific images are used to calculate t-values (C). The original error map was obtained by dividing PET based on Atlas-AC by that on CT-AC, followed by normalization identical to that used for the ADNI-PET data (D, F). We multiplied the normalized PET (B) with each normalized error map (D and F), followed by calculation of the t-value map of the simulated PET (not shown in this figure). The error of the t-value maps was obtained by subtracting the original t-value map from the simulated t-value map (E and G). More detailed figures are shown in [S2 Fig](#pone.0233886.s002){ref-type="supplementary-material"}.](pone.0233886.g004){#pone.0233886.g004}

Discussion {#sec016}
==========

In the current study, we estimated the diagnostic accuracy of FDG-PET with vendor-provided atlas AC from PET/MR (GE SIGNA) for AD. This was achieved by simulating the error introduced by MRAC on ADNI data and investigating the subsequent effect on an automated method for Alzheimer's discrimination. The result shows that error induced by MRAC could lead to an underestimation of the probability of AD. Accuracy and specificity were maintained, but sensitivity for the discrimination of Alzheimer's disease from normal subjects was slightly impaired. A similar slight tendency was found for the prediction of progression from MCI to AD.

There have been few studies evaluating diagnostic accuracy for AD in clinical PET/MR machines that included more than 10 patients. Hitz et al. recruited 30 patients with suspected AD \[[@pone.0233886.ref027]\]. FDG-PET imaging on PET/CT with CTAC and that on PET/MR with MRAC were generated separately. Quantitative analysis showed that inconsistent over- and underestimation, depending on the anatomical region, was apparent on PET/MR even after normalization to the global mean. In visual assessment, even experienced observer ratings diverged between PET/CT and PET/MR in 3 out of 29 patients. In this study, they used Dixon-based MRAC, which is no longer recommended for use in brain PET/MR imaging, and generated PET data for each modality from different PET raw data \[[@pone.0233886.ref028]\]. Our goal was to evaluate the vendor-provided atlas AC, and to use the same PET raw data in the generation of error maps.

Moodley et al. enrolled 24 dementia patients \[[@pone.0233886.ref029]\]. However, the main focus of their study was to evaluate the concordance between FDG-PET and MRI in dementia patients, rather than the validation of MRAC compared with the gold standard: FDG-PET derived from CTAC.

Further studies have been published on the validation of MRAC for brain FDG-PET, some of which recruited AD patients \[[@pone.0233886.ref010], [@pone.0233886.ref030], [@pone.0233886.ref031]\]. However, the main focus of these studies was to clarify the extent and distribution of error introduced by MRAC. None of these studies evaluated the impact of these errors on the diagnostic accuracy for AD in an objective manner. In addition, these studies were performed on different MR systems with different underlying PET-technology, i.e. the Siemens mMR. There is evidence that the time-of-flight (TOF) capability of the GE SIGNA PET/MR might compensate for errors introduced by MRAC \[[@pone.0233886.ref012]\].

We used a fully automated, commercially available, Alzheimer's discrimination analysis to calculate a predictive value for AD. The normal database of FDG PET images used for the discrimination (calculation of t-value) in this tool were acquired on conventional PET/CT scanners \[[@pone.0233886.ref015]\]. Based on our study alone, it is difficult to determine whether a PET/MR-specific FDG-PET database should be constructed \[[@pone.0233886.ref027]\]. However, our finding that diagnostic accuracy was maintained between FDG-PET/MR with atlas-based MRAC and PET/CT indicates that the database for FDG-PET/CT could be used for FDG-PET/MR.

A recent multi-center trial revealed that some novel MRAC methods could generate near "gold standard" AC-maps from MR data on PET/MR \[[@pone.0233886.ref030]\]. In addition, deep-learning-based MRAC methods have been validated and provided prominent accuracy \[[@pone.0233886.ref032]--[@pone.0233886.ref034]\]. However, implementation and adoption on commercially available systems will certainly vary among vendors and users. At most institutions with a PET/MR scanner, researchers and physicians can only choose between the MRAC provided by the vendor, a multi-atlas based method available via a web interface (<http://cmictig.cs.ucl.ac.uk/niftyweb/program.php?p=PCT>) or their own reconstruction algorithm \[[@pone.0233886.ref012], [@pone.0233886.ref035]\].

There were a number of limitations in our study. First, the data acquisition in patients was heterogeneous and not optimized in all cases for brain PET (short 2 min scan duration and variable post-injection time). Using only 2 min acquisition for brain PET images could limit image quality, despite the use of a state-of-the-art PET/MR scanner with high sensitivity detector \[[@pone.0233886.ref036]\]. To mitigate this, all images were smoothed with a Gaussian filter of 12 x 12 x 12 mm which step has been included in PALZ as one of the analysis steps. In addition, we proved that there was no significant difference of PET score error between short scan time (2min) cohort at InA and relatively longer scan time (10min) cohort at InB. Second, brain PET data was taken from patients imaged for oncologic staging, rather than dedicated brain imaging. However, the error introduced by MRAC primarily results from differences in skull bone detection which is not expected to systematically vary among oncology and AD patients. Third, a limited number of patients, n = 47, were used to generate MRAC error maps. This is substantially smaller than a previous larger cohort study that validated the performance of MRAC (n = 337) \[[@pone.0233886.ref030]\]. In addition, the dataset evaluated in the current study consisted entirely of simulated images which combined PET data on different scanners. In future studies a larger dataset of real patient images should be assessed. Fourth, we chose not to focus on the diagnosis of other types of dementia; e.g. fronto-temporal lobar degeneration, dementia with Lewy bodies and vascular dementia, which is sometimes difficult to distinguish from AD in a clinical setting. Fifth, the outcome measure was derived from a single software tool, and visual assessment by an experienced reader was not included. However, the main focus of this study was not on the tool itself but to assess the diagnostic accuracy of FDG PET from PET/MR with vendor-provided atlas AC for AD, in a controlled manner. This goal was fulfilled by the current study, because the diagnostic concept is similar between software or visual assessment. Sixth, we only evaluated a single atlas-based MRAC method. Cross validation using several MRAC methods, provided by other vendors or researchers, should be performed in the future.

Conclusion {#sec017}
==========

FDG-PET/MR based on atlas-based MR attenuation showed similar diagnostic accuracy than the CT-based method for the diagnosis of Alzheimer\'s disease and the prediction of the progression of mild cognitive impairment to Alzheimer\'s disease using the PMOD-based PALZ software, although with a minor reduction in sensitivity.

Supporting information {#sec018}
======================

###### Overview of the automated Alzheimer's discrimination software (PMOD PALZ) algorithm.

A detailed description is provided in the materials and methods section.

(TIF)

###### 

Click here for additional data file.

###### 

The original PET images extracted from ADNI-cohort (A) were spatially normalized to the SPM99 PET template, followed by smoothing with a Gaussian filter of 12 x 12 x 12 mm. Secondly, voxel values were normalized by dividing each image voxel value by the mean voxel value, averaged within a mask representing voxels with AD-preserved activity (B). The voxel-wise differences between the expected and patient-specific images are used to calculate t-values (C). The error map was obtained by dividing PET based on Atlas-AC by that on CT-AC, followed by the normalization to the identical space as spatially normalized ADNI-PET data. The original error map is shown in figures (D) and (F). We multiplied the normalized PET (B) with each normalized error map (D and F), followed by calculation of the t-value map of the simulated PET (not shown in this figure). The error of the t-value maps was obtained by subtracting the original t-value map from the simulated t-value map (E and G). The yellow VOI corresponds to AD-related voxels. The original PET-score of ADNI-data was 0.9385. The PET-score of simulated data was 1.0478 for pt-11 and 0.9497 for pt-14. More detailed figures are shown in S2 Fig.

(JPG)

###### 

Click here for additional data file.

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>. The primary investigator is Michael W. Weiner, MD. His contact email address is <Michael.Weiner@ucsf.edu>.
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:   Attenuation correction

AD

:   Alzheimer's disease

ADNI

:   Alzheimer Disease Neuroimaging Initiative

CI

:   Confidence interval

FDG

:   2-deoxy-2-\[18F\]fluoro-D-glucose

LAVA-Flex

:   liver acquisition with volume acceleration flex
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:   Mild cognitive impairment

MR

:   Magnetic resonance
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: PONE-D-19-22678

The manuscript presents the impact of a MRAC product on FDG PET/MR for the evaluation of Alzheimer's disease (AD). The authors generated 47 PET error maps using the ratio of PET-MRAC/PET-CTAC and applied them to 203 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases after the identical normalization and smoothing. The results show that only sensitivity was slightly impaired in 5 out of 47 datasets for the discrimination of AD-patients from normal controls; however, the accuracy, sensitivity and specificity for predicting progression from mild cognitive impairment (MCI) to AD were not impaired. Thus, the study demonstrated that MRAC showed similar diagnostic accuracy to CTAC for the diagnosis of AD and the prediction of progression of MCI to AD. However, there are so many limitations in the study specifically in the data acquisition (PET data from PET/MR) and data processing (normalization and smoothing), which impairs the reliability of this study.

• The novelty of this study is on investigating the impact of MRAC on the diagnostic and prognostic accuracy of AD using PET images. However, since the impact of MRAC on PET images are very deeply investigated in a bunch of publications specifically for brain PET MRAC, the importance of this study is scientifically weak. Also, the diagnosis/prognosis is solely dependent on the commercial product (PMOD), which also reduces scientific interest towards this study.

• Also, the investigation was done through simulation, which impaired the reliability of this study because (1) spatial normalization and smoothing was applied to PET images for generating PET error maps (e.g., "To mitigate this, all images were smoothed with a Gaussian filter of 12 x 12 x 12 mm"), (2) PET data (from PET/MR) were not acquired in brain protocols (i.e., low quality as mentioned in the discussion) and (3) the error maps were applied to ADNI cases after normalization and smoothing. Considering the low resolution of PET images, the pre/post processing (e.g. spatial normalization to MNI space) can reduce or impair AD-associate information in final images.

• The authors do not demonstrate the accuracy of co-registration between CT and MR images, which is critical for the accuracy of generating PET error maps.

• The authors did not refer up-to-date publications regarding MRAC. Specifically, deep learning for directly converting MR to CT images has been well demonstrated in several publications.

1\. Deep Learning MR Imaging-based Attenuation Correction for PET/MR Imaging. (2017)

2\. Attenuation correction for brain PET imaging using deep neural network based on Dixon and ZTE MR images (2017)

3\. Etc.

• "Our goal was to evaluate the state-of-the-art vendor-provided atlas AC, and to use the same PET raw data in the generation of error maps." I can't agree with this point that the atlas-based AC is the state-of-the-art.

• "We used a fully automated, commercially available, Alzheimer's discrimination analysis to calculate a predictive value for AD". If this manuscript is based on the partnership with the commercial product (PMOD), it should be clarified as a conflict-of-interest.

• There are too many limitations (as stated in the discussion) to consider that the results are scientifically reliable.

Reviewer \#2: The author presented a study, to investigate the impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases using simulation data in manner of multi-center study. However, some critical problems exist in the methodology and the results should be addressed before considering for publication.

Introduction.

This part presented well, however I suggest to include one paragraph on more recent approaches on PET attenuation and scatter correction such as Deep Learning base methods.

Arabi, H., Zeng, G., Zheng, G., & Zaidi, H. (2019). Novel adversarial semantic structure deep learning for MRI-guided attenuation correction in brain PET/MRI. European journal of nuclear medicine and molecular imaging, 46(13), 2746-2759.

Shiri, Isaac, et al. \"Direct attenuation correction of brain PET images using only emission data via a deep convolutional encoder-decoder (Deep-DAC).\" European radiology 29.12 (2019): 6867-6879.

Sgard, Brian, et al. \"ZTE MR-based attenuation correction in brain FDG-PET/MR: performance in patients with cognitive impairment.\" European radiology (2019): 1-10.

Methods:

The methods part is not provided very well and can't be easily follow, I suggest to provide a flowchart and show the steps on this paper.

Please provide patients and demographic and clinical characteristics for each data sets.

Major comments:

Authors mentioned that, they enrolled patients with brain tumors, brain metastasis for generating the error maps. The propose methods was for AD, however the error map which provided for simulation data were provided on cancer and metastasis patients. These two dataset are totally different in nature and also the pattern. So, in my opinion the cancer data set is not suitable to provide the error map then apply on AD. I highly recommend to provide the error map using Normal or AD patients, because of different uptake, different distribution and pattern of brain.

Data for generation the error map (for simulation purpose) included the PSF and TOF information, dose the ADNI dataset included these information? The TOF information provided very useful information which help the attenuation correction in PET, if the ADNI doesn't included the TOF information, then the generated maps shouldn't also.

Providing error map using TOF dataset and then applying on non-TOF would be one of the main challenges, the authors should produce error map from non-TOF error map or apply the error map on AD images with TOF.

I would like to ask the authors to provide the error (i.e relative error) of each regions (respect to ground truth) using pmod atlas (i.e the Hammers maximum probability atlas), for comparing the CTAC and MRAC to show how the error map effect on datasets, rather than comparing on diagnostic analysis. Please provide the error of simulated datasets respect to ground truth.

Comparing the methods only on final results without showing what happened in process is not sufficient as the final results is depend on many parameters, then it's not possible to explain why it does work or not working.

Results

Results part is to short, please explain more about the results, i.e how the map effect on datasets. An average error of either whole brain can assess the physical performance of the method. However, It possible that the errors of the each region (using atlas in PMOD) which is more important in AD diagnosis are higher than the whole brain error. The authors should be aware of this issue and then report the error of important regions in AD (to compare two methods)

Discussion

Authors provided the limitation of present study very well, I'm wondering about the dataset acquired with 2min which can lead to main issue in quantification (it's almost low dose PET which is not clinically applicable in AD), I suggest to remove these data and re-evaluate or bring some background or justification for these data.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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5\. Review Comments to the Author

Reviewer \#1: PONE-D-19-22678

The manuscript presents the impact of a MRAC product on FDG PET/MR for the evaluation of Alzheimer's disease (AD). The authors generated 47 PET error maps using the ratio of PET-MRAC/PET-CTAC and applied them to 203 Alzheimer's Disease Neuroimaging Initiative (ADNI) cases after the identical normalization and smoothing. The results show that only sensitivity was slightly impaired in 5 out of 47 datasets for the discrimination of AD-patients from normal controls; however, the accuracy, sensitivity and specificity for predicting progression from mild cognitive impairment (MCI) to AD were not impaired. Thus, the study demonstrated that MRAC showed similar diagnostic accuracy to CTAC for the diagnosis of AD and the prediction of progression of MCI to AD. However, there are so many limitations in the study specifically in the data acquisition (PET data from PET/MR) and data processing (normalization and smoothing), which impairs the reliability of this study.

Thank you for your many valuable comments.

• The novelty of this study is on investigating the impact of MRAC on the diagnostic and prognostic accuracy of AD using PET images. However, since the impact of MRAC on PET images are very deeply investigated in a bunch of publications specifically for brain PET MRAC, the importance of this study is scientifically weak.

As the reviewer pointed out, there have been vast of published MRAC studies some of which included dementia patients. However, as described in the discussion part, there is very few or almost no paper to focus on the diagnostic accuracy of AD using commercially available MRAC method. From this point of view, we think that our study has substantial scientific merit.

Also, the diagnosis/prognosis is solely dependent on the commercial product (PMOD), which also reduces scientific interest towards this study.

The main focus of this study was not the performance of sole program itself. As described in the limitation section, the diagnostic concept is similar between PALZ and other software or even in visual assessment. PALZ package is standard analysis protocol which has been widely validated in large cohort study (e.g. ADNI, NEST-DD and SEAD-Japan) and used in clinical setting.

• Also, the investigation was done through simulation, which impaired the reliability of this study because (1) spatial normalization and smoothing was applied to PET images for generating PET error maps (e.g., "To mitigate this, all images were smoothed with a Gaussian filter of 12 x 12 x 12 mm"), (2) PET data (from PET/MR) were not acquired in brain protocols (i.e., low quality as mentioned in the discussion) and (3) the error maps were applied to ADNI cases after normalization and smoothing. Considering the low resolution of PET images, the pre/post processing (e.g. spatial normalization to MNI space) can reduce or impair AD-associate information in final images.

\(1\) This spatial normalization is one of the main steps in PALZ protocol. This step was not tailored for error map generation in the current study. The main purpose of this spatial normalization to error map was to generate simulation map combining ADNI data and real patients' data in the same spatially normalized space. To clarify it, we added the sentence as below. "To mitigate this, all images were smoothed with a Gaussian filter of 12 x 12 x 12 mm which step has been included in PALZ as one of the analysis steps."

\(2\) More than half of patients (27 patients at InB) in this study underwent 10-minutes PET scan which was expected to have sufficient image quality on high-sensitivity PET/MR system with SiPM detector. We proved that the difference of PET score error between InA and InB was not significantly different (-0.070±0.045 vs. -0.066±0.046; p=0.392). We have added this statement in the limitation section. In addition, if the 2min acquisition leads to substantial error even after applying large Gaussian filter, the PET score difference was expected to be under or overestimated than the ideal situation. It means that our main result that Atlas-based MRAC is accurate would be maintained even in the ideal situation.

\(3\) As described above, normalization and smoothing is one of the main steps of general PALZ analysis steps. The main purpose of this step is to compensate the difference of SNR or spatial resolution among institutions. The diagnostic accuracy of original ADNI data is maintained after this step (83.2%) as shown in the result section.

• The authors do not demonstrate the accuracy of co-registration between CT and MR images, which is critical for the accuracy of generating PET error maps.

We used a standard method of co-registration between two modalities, mutual information matching algorithm by using widely available software (Pmod). We agree that the registration error may overestimate the error from MRAC. However, this overestimation has subtle impact on our main conclusion that MRAC can maintain the diagnostic accuracy for the diagnosis of AD. If the reviewer suggests, we will add this topic to the limitation section.

• The authors did not refer up-to-date publications regarding MRAC. Specifically, deep learning for directly converting MR to CT images has been well demonstrated in several publications.

1\. Deep Learning MR Imaging-based Attenuation Correction for PET/MR Imaging. (2017)

2\. Attenuation correction for brain PET imaging using deep neural network based on Dixon and ZTE MR images (2017)

3\. Etc.

We have added some references regarding deep-learning-based MRAC. Thank you.

• "Our goal was to evaluate the state-of-the-art vendor-provided atlas AC, and to use the same PET raw data in the generation of error maps." I can't agree with this point that the atlas-based AC is the state-of-the-art.

We agree that Atlas-MRAC is no longer state-of-the-art method. We have deleted "state-of-the-art" method.

• "We used a fully automated, commercially available, Alzheimer's discrimination analysis to calculate a predictive value for AD". If this manuscript is based on the partnership with the commercial product (PMOD), it should be clarified as a conflict-of-interest.

We used only commercially available functions on Pmod. We already stated as "Automated AD probability assessment was performed in a commercially available tool (PMOD Alzheimer's Discrimination, PALZ).". If the reviewer suggested that we will add some more statements.

• There are too many limitations (as stated in the discussion) to consider that the results are scientifically reliable.

We agree that there are too many limitations. However, each limitation is not so critical.

\[1\] Some of PET data for error map generation was done from 2min brain PET scan. However, we proved that 2min brain PET scan didn't overestimate/underestimate the final result compared to 10 min brain PET scan.

\[2\] PET data was taken from oncologic patients. However, MRAC error was mainly derived from the head skull which does not vary among oncologic patient and dementia subjects.

\[3\] We stated the sample size is small. To be honest, n=47 is not critically small in this kind of study.

\[4\] We only assessed AD-related diagnostic accuracy. To be honest, this setup is a common study design in the diagnostic accuracy of dementia.

\[5\] Outcome measure was done by PALZ software. The diagnostic concept in PALZ software is similar in other software or visual assessment. The detection of AD-related uptake change is the key diagnostic process. We think that the method in the current study is relatively objective because whole process was done semi-automatically.

\[6\] We validated the sole MRAC method, Atlas-AC. This method is one of the main commercially available attenuation correction methods on GE-PET/MR which is widely used in the clinical setting.

Reviewer \#2: The author presented a study, to investigate the impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases using simulation data in manner of multi-center study. However, some critical problems exist in the methodology and the results should be addressed before considering for publication.

Thank you for your many valuable comments.

Introduction.

This part presented well, however I suggest to include one paragraph on more recent approaches on PET attenuation and scatter correction such as Deep Learning base methods.

Arabi, H., Zeng, G., Zheng, G., & Zaidi, H. (2019). Novel adversarial semantic structure deep learning for MRI-guided attenuation correction in brain PET/MRI. European journal of nuclear medicine and molecular imaging, 46(13), 2746-2759.

Shiri, Isaac, et al. \"Direct attenuation correction of brain PET images using only emission data via a deep convolutional encoder-decoder (Deep-DAC).\" European radiology 29.12 (2019): 6867-6879.

Sgard, Brian, et al. \"ZTE MR-based attenuation correction in brain FDG-PET/MR: performance in patients with cognitive impairment.\" European radiology (2019): 1-10.

We have added suggested references. Thank you.

Methods:

The methods part is not provided very well and can't be easily follow, I suggest to provide a flowchart and show the steps on this paper.

We had already provided the flow chart of each process in figure 1 and supplemental figure 1. To improve readability, we have added the statement of referred figure in the first paragraph of materials and methods section where the summary of whole steps was described.

Please provide patients and demographic and clinical characteristics for each data sets.

We have added the detailed information for each dataset.

Major comments:

Authors mentioned that, they enrolled patients with brain tumors, brain metastasis for generating the error maps. The propose methods was for AD, however the error map which provided for simulation data were provided on cancer and metastasis patients. These two dataset are totally different in nature and also the pattern. So, in my opinion the cancer data set is not suitable to provide the error map then apply on AD. I highly recommend to provide the error map using Normal or AD patients, because of different uptake, different distribution and pattern of brain.

We expected that the morphology without atrophy, and specific FDG-uptake distribution of oncology patients may not induce a large effect on the FDG-uptake error led by MRAC. The error is mainly caused by the error of the skull bone estimation by atlas-MRAC. This topic was already mentioned in the limitation part as "the error introduced by MRAC primarily results from differences in skull bone detection which is not expected to systematically vary among oncology and AD patients.".

Data for generation the error map (for simulation purpose) included the PSF and TOF information, dose the ADNI dataset included these information? The TOF information provided very useful information which help the attenuation correction in PET, if the ADNI doesn't included the TOF information, then the generated maps shouldn't also.

Providing error map using TOF dataset and then applying on non-TOF would be one of the main challenges, the authors should produce error map from non-TOF error map or apply the error map on AD images with TOF.

The main goal of this study was to combine a well-controlled dataset and clinically realistic error map. There is no clinical situation that MRAC without TOF reconstruction on GE PET/MR scanner because TOF reconstruction reduces the error from MRAC. Ideally, well-controlled PET data with TOF reconstruction should be used. However, such open-data is not accessible yet.

We agree that this point is the main drawback of our simulation study. To clarify it, we have added the comment in the limitation part as "In addition, the dataset evaluated in the current study consisted entirely of simulated images which combined PET data on different scanner."

I would like to ask the authors to provide the error (i.e relative error) of each regions (respect to ground truth) using pmod atlas (i.e the Hammers maximum probability atlas), for comparing the CTAC and MRAC to show how the error map effect on datasets, rather than comparing on diagnostic analysis. Please provide the error of simulated datasets respect to ground truth.

Comparing the methods only on final results without showing what happened in process is not sufficient as the final results is depend on many parameters, then it's not possible to explain why it does work or not working.

We already showed that detail of MRAC error in other papers (Delso G. Neuroimage 2018;181:403-413. and Sekine T. J Nucl Med 2016;57:1927-1932.).

To avoid the duplication, we only added the evaluation about the error distribution.

In "Evaluation of diagnostic accuracy of Alzheimer's disease" we have amended as below.

"First, to clarify the distribution of MRAC error, we calculated the averaged error in whole SPM 99 PET voxels, whole AD-related voxels and whole non-AD related voxels in each of the 47 normalized error map ((\_Error\^Norm)〖PET〗\_ \^(pt-i))."

In result section, we have amended as below

"In 47 normalized error map, whole voxels of SPM 99 were slightly underestimated (-1.37%±1.98%). In detail, AD-related voxels were less underestimated than non AD-related voxels (-0.86%±2.03% vs. -1.59%±1.98%)."

Results

Results part is to short, please explain more about the results, i.e how the map effect on datasets. An average error of either whole brain can assess the physical performance of the method. However, It possible that the errors of the each region (using atlas in PMOD) which is more important in AD diagnosis are higher than the whole brain error. The authors should be aware of this issue and then report the error of important regions in AD (to compare two methods)

As described above, we added the evaluation of the error distribution caused by MRAC. The additional analysis shows that AD-related voxels were less underestimated (-0.86%) than non AD-related voxels (-1.59%). It means that AD-related voxels were overestimated after value-normalization, resulting in decreasing t-value. It is in line with the result that PET score was slightly underestimated (-0.068).

Discussion

Authors provided the limitation of present study very well, I'm wondering about the dataset acquired with 2min which can lead to main issue in quantification (it's almost low dose PET which is not clinically applicable in AD), I suggest to remove these data and re-evaluate or bring some background or justification for these data.

More than half of patients (27 patients at InB) in this study underwent 10-minutes PET scan which was expected to have sufficient image quality on high-sensitivity PET/MR system with SiPM detector. We proved that the difference of PET score error between InA and InB was not significantly different (-0.070±0.045 vs. -0.066±0.046; p=0.392). We have added this statement in the limitation section. In addition, if the 2min acquisition leads to substantial error even after applying large Gaussian filter, the PET score difference was expected to be under- or overestimated than the ideal situation. It means that our main result that Atlas-based MRAC is accurate would be maintained even in the ideal situation.
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Dear Dr. Sekine,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.
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Thomas Pyka
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?
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